about
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.Key drivers for market penetration of biosimilars in Europe.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases.Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsPolicy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.The role of biosimilars in value-based oncology care
P2860
Q30399745-A06525D3-7FAA-40A2-839C-5EFA7CA0E488Q33713947-B58F559B-5FBE-48AE-9737-7A6871E5B6DBQ36759817-D713FC91-F1D6-460B-B0B9-F62AED134FB4Q37669625-D783493E-5CF2-4015-B52C-2382EDC706A4Q38641699-DBECBBFA-CE62-4099-9544-302109CE6D8FQ38841536-870E2EF6-EC42-497C-A762-902AEFD58F88Q38977625-9094B518-C349-4763-B1C0-E7D7CA84BDA1Q39072439-F5F979D2-DF47-4297-A61D-E0FCF3962539Q39348676-3DD836DF-C301-4C96-9C58-853325A0B91BQ39403982-B306E2DF-D88F-416C-89D9-D8DD6BCAE6F5Q39455869-5E4A9C8A-7E58-4073-825F-7EACD550F2F1Q42370596-2ACD39EF-FF62-4521-AE43-A5376B97D32CQ48092457-AB167550-F94D-42D1-B608-027D1B69AB7FQ48287588-CEEAA7AC-923D-4F7F-9DBC-FE77AE045095Q50483003-1FF4A197-862F-43C0-B9E4-EF57300E3BA5Q51022840-34A642F8-CDF2-4CEB-8B5B-893E803427C0Q58605622-75D8F4A2-62A8-4621-84D7-17C3605FA056
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biosimilars: How Can Payers Get Long-Term Savings?
@ast
Biosimilars: How Can Payers Get Long-Term Savings?
@en
type
label
Biosimilars: How Can Payers Get Long-Term Savings?
@ast
Biosimilars: How Can Payers Get Long-Term Savings?
@en
prefLabel
Biosimilars: How Can Payers Get Long-Term Savings?
@ast
Biosimilars: How Can Payers Get Long-Term Savings?
@en
P2093
P2860
P3181
P1433
P1476
Biosimilars: How Can Payers Get Long-Term Savings?
@en
P2093
Adrian Towse
Jorge Mestre-Ferrandiz
Mikel Berdud
P2860
P2888
P304
P3181
P356
10.1007/S40273-015-0380-X
P407
P577
2016-06-01T00:00:00Z